All In Biotech

Drug Trial Radar · NCT04351685

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

A Multicenter, Phase III, Double-blind, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Mycobacterium Tuberculosis Infection in Newborn Infants

Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,940 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,940

Actual

Start

Nov 9, 2020

Primary completion

Oct 30, 2024

Study completion Oct 30, 2024

Sponsor

Sponsor type
Industry
Collaborators
Serum Life Science Europe GmbH
First posted
Apr 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 0 days, up to 14 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation) to assess the efficacy, safety and immunogenicity of VPM1002 against Mtb infection.

Conditions

  • Mycobacterium Tuberculosis Infection

Interventions

  • VPM1002Biological

    The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally. Manufactured by the Serum Institute of India Pvt. Ltd., India Diluent: 1 ml of Water for injection/vial

  • BCG SIIBiological

    Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally. Manufactured by the Serum Institute of India Pvt. Ltd., India Diluent: 1 ml of Sodium Chloride for injection/vial Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incident cases of QFT conversion, indicating Mtb infectionTime frame: Minimum of 12 months and maximum of 36 months

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • Centre de Recherches Médicales de Lambaréné

    Lambaréné, Gabon

  • Kenya Medical Research Institute / Center for Respiratory Disease Research

    Nairobi, Kenya

  • Kenya Medical Research Institute - Center for Respiratory Disease Research

    Siaya, Kenya

  • Family Center for Research with Ubuntu

    Cape Town, South Africa

  • Mecru Clinical Research Unit

    Medunsa, South Africa

  • Respiratory and Meningeal Pathogens Research Unit

    Soweto, South Africa

  • South African Tuberculosis Vaccine Initiative

    Worcester, South Africa

  • Empilweni Services and Research Unit (ESRU)

    Johannesburg, Coronation Ville, South Africa

  • Ifakara Health Institute

    Dar es Salaam, Tanzania

  • The national institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC)

    Mbeya, Mbeya, Tanzania

  • Medical Research Council / Uganda Virus Research Institute and London School of Hygiene and Tropical Medicines (MRC/UVRI and LSHTM) Uganda Research Unit

    Entebbe, Uganda

  • Makerere University/CISMAC

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.